| (USD) | Sep 2023 | Q/Q |
|---|---|---|
| Revenue | 8.8MM | -6% |
| Gross Profit | 5.6MM | -7% |
| Cost Of Revenue | 3.2MM | -6% |
| Operating Income | -7.4MM | +12% |
| Operating Expenses | 13MM | +3% |
| Net Income | -9.2MM | +49% |
| R&D | 3.7MM | +2% |
| G&A | 8.1MM | +5% |
| Professional Service | 1.1MM | -7% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
PRINCETON, N.J., April 17, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, today announced that topline results from its pivotal U.S. and Canadian Safe and Timely Antithrombotic Removal of Ticagrelor (STAR-T) randomized controlled trial will be featured as a late-breaking clinical trial presentation a
By Thomas Kerr, CFA NASDAQ:CTSO READ THE FULL CTSO RESEARCH REPORT For the full year 2023, total revenues increased approximately 5.0% to $36.3 million. Total product sales were $31.1 million, an increase of 6.0% from 2022. 2022 sales benefitted from $0.7 million in other non-CytoSorb sales and $0.3 million in COVID-19 related sales that did not recur in 2023. Core (non-Covid-19 related) CytoSorb
The analysts covering Cytosorbents Corporation ( NASDAQ:CTSO ) delivered a dose of negativity to shareholders today, by...
Cytosorbents ( NASDAQ:CTSO ) Full Year 2023 Results Key Financial Results Revenue: US$36.3m (up 4.8% from FY 2022). Net...
Cytosorbents Corporation (NASDAQ:CTSO) Q4 2023 Earnings Call Transcript March 14, 2024 Cytosorbents Corporation isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon, and welcome to the CytoSorbents’ Fourth Quarter and Full-Year 2023 Financial and Operating Results Conference Call. At […]
Q4 2023 Cytosorbents Corp Earnings Call
STAR-T trial results selected for a Breakout Presentation at the American Association of Thoracic Surgery Annual Meeting in late-April 2024 CytoSorbents intends to submit DrugSorb-ATR for regulatory approval to U.S. Food & Drug Administration (FDA) and Health Canada this year CytoSorb core sales increased approximately 10% year-over-year 2023 Product gross margins increased to 72% Cumulative CytoSorb treatments surpassed 228,000 PRINCETON, N.J., March 14, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Co
PRINCETON, N.J., March 06, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will report fiscal 2023 financial results on Thursday, March 14th, 2024 at 4:30PM EDT. CytoSorbents’ management will host a live conference call and presentation webcast that will recount both operational and financial progress during Q4 2023 and fiscal year ending December 31
As every investor would know, not every swing hits the sweet spot. But you have a problem if you face massive losses...
PRINCETON, N.J., Feb. 08, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announces that Dr. Phillip Chan, Chief Executive Officer, will present at the TD Cowen 44th Annual Health Care Conference at the Boston Marriott Copley Place, in Boston, MA on Wednesday, March 6th, 2024. Company management will also meet in-person with investors in 1x1 meetings